Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| SUPPLEMENTAL INFORMATION | Part III, LINE 1 | ORGANIZATION'S MISSION The Susan G. Komen for the Cure Advocacy Alliance (KAA) is the non-profit, non-partisan advocacy organization that provides a voice for the 2.9 million breast cancer survivors and those who love them. As such, KAA works to educate and encourage lawmakers, candidates, and government leaders to support legislative, regulatory and other policies that will help end breast cancer forever. Part III, LINES 4A-4C State Issues: Education and Advocacy KAA developed and implemented various education and advocacy initiatives to encourage state elected and agency officials to support policies and legislation that further the overall mission to end breast cancer forever. KAA coordinated various grassroots campaigns to mobilize the KAA network of breast cancer advocates in support of those initiatives. These efforts helped to preserve over $107 million in state funding for safety net breast cancer screening programs that serve low income, uninsured and underinsured women. KAA was also involved in efforts to expand insurance coverage for orally-administered anti-cancer medications and expand access to Medicaid-funded treatment services under the Breast & Cervical Cancer Treatment Act. Federal Issues: Education and Advocacy Through education, outreach, advocacy initiatives and regulatory comment letters, KAA worked to encourage federal lawmakers, agency heads, and candidates to support and implement programs, legislation, and policies that advance our mission of ending breast cancer forever. Specifically, KAA, with the support of its network of breast cancer advocates, engaged in efforts to educate lawmakers about the importance of early detection and to encourage their support for funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) and for continuing to invest in breast cancer research. These efforts helped to maintain $206 million for NBCCEDP in the FY12 budget and $30.698 billion for the NIH budget (an increase of 1%) and $5.081 billion for the NCI budget (an increase of 1%). KAA has also focused on advocating for policies that directly serve individuals with breast cancer, survivors, and those who may develop breast cancer in the future, such as providing access to and coverage for quality preventive programs as well as affordable and quality treatment for women and men facing breast cancer. Additionally, KAA focused its advocacy efforts on oral chemotherapy parity, drug shortages, FDA approval, and addressing health care disparities. KAA submitted ten regulatory comment letters to ensure that health care legislation is implemented in a manner that takes into account the needs of those impacted by breast cancer. The topics of these comment letters included setting up health insurance exchanges, addressing drug shortages, defining an essential benefits package, and recommendations for the Patient Centered Outcomes Research Institute (PCORI) research agenda. Grassroots Outreach and Education. KAA actively recruited advocates to further strengthen its grassroots advocacy network. KAA also implemented various programs to educate and engage advocates in breast cancer policy issues. |
| Member Election | Form 990, Part VI, Question 6, 7a & 7b | Susan G. Komen for the Cure Advocacy Alliance's corporate documents provide for a sole Class A Voting Member and Class B Non-Voting Members. The sole Class A Voting Member is The Susan G. Komen Breast Cancer Foundation, Inc. Currently, there are no Class B Non-Voting Members. The Class A Voting Member may elect up to 15 members of the 31 maximum member Board of Directors, but in no event will the Board of Directors have more than one less Class A Director than non-Class A Directors. The Class A Voting Member may elect 4 members of the 9 member Executive Committee of the Board of Directors, with the remaining 5 members elected by the Board. The Class A Voting Member approves all Non-Class A directors elected to the Board and to the Executive Committee. The Board of Directors needs the affirmative vote of the Class A Voting Member for any amendment or restatement of the Certificate of Formation, adoption, material alteration, material amendment or repeal of the Bylaws, any merger, creation of or dissolution of any subsidiaries or other legally-related organizations, entry into any contracts with a value in excess of $500,000 in the aggregate, material modification of the Susan G. Komen for the Cure Advocacy Alliance's tax exempt status, sale of all or substantially all of the assets, conveyance of any real property, plan of conversion, plan of exchange, voluntary winding up or plan of distribution of the Susan G. Komen for the Cure Advocacy Alliance. |
| Describe the Process used by Management &/or Governing Body to Review 990 | Form 990, Part VI, Question 11B | MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVELS OF MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR PRESENTATION TO THE BOARD. The Board or the Executive Committee of the Board of Directors reviews and approves the Form 990 prior to being filed. Thereafter, each member of the Board of Directors receives an electronic copy of the Form 990 via email prior to the form being filed. |
| Description of Process to Monitor Transactions for Conflicts of Interest | Form 990, Part VI, Question 12c | The organization produces an annual survey requiring all employees, board members, committee members and advisory boards to inform on conflicts. Any conflicts are then reviewed by management and the audit committee and appropriate measures are taken. In addition, those same people have the obligation to update the conflict of interest statements during the year. |
| Offices & Positions for Which Process was Used, & Year Process was Begun | Form 990, Part VI, Question 15a & 15b | Beginning in 2007, the Board of Directors oversees compensation policies and practices. Responsibilities include oversight of the compensation of the top management official, the range of compensation levels for the Organization's employees, and incentive/bonus compensation programs. The Organization currently has no employees and utilizes employees of The Susan G. Komen Breast Cancer Foundation, Inc. through a shared services agreement with costs and expenses reimbursed by the Organization. As part of the shared services, the Susan G. Komen for the Cure Advocacy Alliance utilizes the assistance of The Susan G. Komen Breast Cancer Foundation, Inc. in determining appropriate and reasonable compensation levels. The Susan G. Komen Breast Cancer Foundation, Inc. maintains a formal compensation policy that governs pay practices. Periodically, all positions are reviewed against external market data, engaging independent experts to conduct the benchmarking process. Compensation is then based upon comparable market rates of pay with consideration for internal equity and the financial position of the Organization. For the Top Management Official, external benchmarking was conducted again this fiscal year to ensure market alignment. Salary increases, promotions or other forms of compensation are provided without regard to race, color, religion, gender, national origin, disability, veteran status or sexual orientation. |
| Avail of Gov Docs, Conflict of Interest Policy, & Fin Stmts to Gen Public | Form 990, Part VI, Question 19 | The Organization's financial statements, conflict of interest policy and the 990 are publicly available on our website. The Articles of Incorporation are available from the Texas Secretary of State and other governing documents are made available as required by state law. Form 1023 is not online but available to the public upon request. Additionally, improper conduct concerns are filed on the Komen.org website. |
| Software ID: | |
| Software Version: |